Microbubbles coupled to methotrexate-loaded liposomes for ultrasound-mediated delivery of methotrexate across the blood-brain barrier.

Abstract

Methotrexate (MTX) is the single most effective agent for the treatment of primary central nervous system lymphoma. Currently, the delivery of MTX to the brain is achieved by high systemic doses, which cause severe long-term neurotoxicity, or intrathecal administration, which is highly invasive and may lead to infections or hemorrhagic complications. Acoustically active microbubbles have been developed as drug carriers for the noninvasive and brain-targeted delivery of therapeutics. However, their application is limited by their low drug-loading capacity. To overcome this limitation, we prepared microbubbles coupled to MTX-loaded liposomes using ZHIFUXIAN, a novel type of microbubbles with a superior safety profile and long circulation time. MTX-liposome-coupled microbubbles had a high drug-loading capacity of 8.91%± 0.86%, and their size (2.64 ± 0.93 μm in diameter) was suitable for intravenous injection. When used with ultrasound, they showed more potent in vitro cytotoxicity against Walker-256 cancer cells than MTX alone or MTX-loaded liposomes. When Sprague-Dawley rats were exposed to sonication, administration of these MTX-liposome-coupled microbubbles via the tail vein led to targeted disruption of the blood-brain barrier without noticeable tissue or capillary damage. High-performance liquid chromatography analysis of the brain MTX concentration showed that MTX delivery to the brain followed the order of MTX-liposome-coupled microbubbles + ultrasound (25.3 ± 2.4 μg/g) > unmodified ZHIFUXIAN + MTX + ultrasound (18.6 ± 2.2 μg/g) > MTX alone (6.97 ± 0.75 μg/g) > MTX-liposome-coupled microbubbles (2.92 ± 0.39 μg/g). Therefore, treatment with MTX-liposome-coupled microbubbles and ultrasound resulted in a significantly higher brain MTX concentration than all other treatments (P<0.01). These results suggest that MTX-liposome-coupled microbubbles may hold great promise as new and effective therapies for primary central nervous system lymphoma and other central nervous system malignancies.

• Authors: Xiang Wang, Ping Liu, Weixiao Yang, Lu Li, Peijing Li, Zheng Liu, Zhongxiong Zhuo, Yunhua Gao
• Journal: International journal of nanomedicine (Int J Nanomedicine) Vol. 9 Pg. 4899-909 ( 2014) ISSN: 1178-2013 [Electronic] New Zealand
• PMID: 25364248 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Liposomes
• Evans Blue
• Methotrexate

Topics

• Animals
• Antineoplastic Agents (chemistry, pharmacokinetics, pharmacology)
• Blood-Brain Barrier (metabolism)
• Brain (drug effects, pathology)
• Brain Chemistry
• Cell Line, Tumor
• Cell Proliferation (drug effects)
• Cell Survival (drug effects)
• Evans Blue (chemistry)
• Liposomes (chemistry, pharmacokinetics)
• Methotrexate (chemistry, pharmacokinetics, pharmacology)
• Microbubbles
• Rats
• Rats, Sprague-Dawley
• Sonication